Kratom living monograph
Activating, sedating, and adverse kratom effects, with source-linked evidence and product uncertainty.
Effects
Kratom is not a single compound. Subjective effects and adverse effects depend on alkaloid profile, product form, exposure, tolerance, context, and co-use. A simple “stimulating at low amounts, sedating at high amounts” rule is too crude.
Surveys describe alertness, energy, talkativeness, or feeling more functional. These observations do not establish a classic stimulant mechanism or a reliable product class.
Drug and Alcohol Dependence, 2017National Institute on Drug Abuse (NIDA), 2025Relaxation, warmth, reduced pain perception, tiredness, and an opioid-like body sensation are reported. Greater sedation raises risk, especially with other depressants.
Drug and Alcohol Dependence, 2017Journal of the American Chemical Society, 2016Bundesinstitut für Risikobewertung (BfR), 2025Nausea, vomiting, constipation, dizziness, drowsiness, sweating, itching, agitation, or palpitations are described. Product heterogeneity prevents reliable prediction of frequency and severity.
Bundesinstitut für Risikobewertung (BfR), 2025National Center for Complementary and Integrative Health, 2025WHO Expert Committee on Drug Dependence, 2021Reported severe presentations include seizures, altered consciousness, profound sedation, breathing problems, and liver injury. Many severe cases involve co-use or uncertain products, which complicates causality without removing the safety signal.
WHO Expert Committee on Drug Dependence, 2021Bundesinstitut für Risikobewertung (BfR), 2025Drug and Alcohol Dependence, 2021These labels are not validated pharmacological classes. Colour, processing, batch, blends, and marketing can overlap. A strain name therefore cannot reliably predict alkaloid composition or effects.
Phytochemistry, 2026Bundesinstitut für Risikobewertung (BfR), 2025Product forms
Product form is safety-critical information. Potency, predictability, and the applicability of research evidence differ substantially.
A water-based leaf preparation with a variable alkaloid profile. Human tea studies apply only to the analysed study product.
Preparation and plant material alter the actual exposure.
Drug and Alcohol Dependence, 2017Clinical Pharmacology & Therapeutics, 2023Dried plant material; batches and alkaloid concentrations still differ.
Gram amounts describe mass, not a reliable active-alkaloid concentration.
Drug and Alcohol Dependence, 2017Phytochemistry, 2026May contain leaf powder or concentrated material. The format alone does not establish strength.
Labelling, fill weight, and alkaloid profile must be assessed separately.
Bundesinstitut für Risikobewertung (BfR), 2025Phytochemistry, 2026Concentrated products for which leaf gram amounts do not transfer.
Ratios such as “10×” are not a reliable potency measure without validated analysis.
Bundesinstitut für Risikobewertung (BfR), 2025Phytochemistry, 2026Concentrated products with a declared mitragynine content. Standardizing one alkaloid does not remove all uncertainty.
Other alkaloids, analytical quality, bioavailability, and conversion to 7-OH remain relevant.
Molecules, 2024Phytochemistry, 2026Tablets, gummies, shots, or mixtures with 7-hydroxymitragynine levels that do not resemble ordinary leaf.
Greater opioid potency, rapid tolerance development, and labelling uncertainty increase risk.
ACS Central Science, 2019Journal of AOAC International, 2026Products without credible ingredient and concentration data cannot be meaningfully classified.
Unexpected substances, contaminants, or materially higher concentrations are possible.
Bundesinstitut für Risikobewertung (BfR), 2025National Institute on Drug Abuse (NIDA), 2025Trust
Each source is tied to a claim domain. “Reviewed” means editorial source review—not individual medical clearance.
Bundesinstitut für Risikobewertung (BfR) · 2025
Contributes: German risk communication on products, adverse effects, and classification.
Limit: Regulatory assessment; emphasises limited evidence and is not a product-specific legal ruling.
WHO Expert Committee on Drug Dependence · 2021
Contributes: Broad international review of pharmacology, toxicity, dependence, and case reports.
Limit: Many severe cases are confounded by co-use and heterogeneous products.
Contributes: Research-based overview of effects, products, dependence, and uncertainties.
Limit: Secondary government overview, not an individual primary study.
Contributes: Government overview of benefit claims, adverse effects, and research limits.
Limit: Secondary source; not product-specific.
Drug and Alcohol Dependence · 2017
Contributes: Large online survey of use patterns and self-reported effects.
Limit: Self-selection, self-report, no product analysis, and no causal inference.
Journal of the American Chemical Society · 2016
Contributes: Receptor and signalling data for Mitragyna alkaloids.
Limit: Predominantly preclinical; cellular signalling is not a clinical safety guarantee.
Phytochemistry · 2026
Contributes: Current analytical evidence on variability across commercial products.
Limit: Product sample does not represent the entire rapidly changing market.
